The impact of 24hr infusions on clinical practice
Transcript of The impact of 24hr infusions on clinical practice
![Page 1: The impact of 24hr infusions on clinical practice](https://reader033.fdocuments.us/reader033/viewer/2022060918/629939fb178ce1594f2e2d59/html5/thumbnails/1.jpg)
The impact of 24hr infusions on clinical practice
Tim HillsNottingham University Hospitals NHS Trust
![Page 2: The impact of 24hr infusions on clinical practice](https://reader033.fdocuments.us/reader033/viewer/2022060918/629939fb178ce1594f2e2d59/html5/thumbnails/2.jpg)
Outline• Why use CIV beta-lactam antibiotics?• Drug-stability work stream• Initial experience of CIV beta-lactams• Clinical Outcomes of there use in OPAT• Future plans
![Page 3: The impact of 24hr infusions on clinical practice](https://reader033.fdocuments.us/reader033/viewer/2022060918/629939fb178ce1594f2e2d59/html5/thumbnails/3.jpg)
PK/PD consideration
![Page 4: The impact of 24hr infusions on clinical practice](https://reader033.fdocuments.us/reader033/viewer/2022060918/629939fb178ce1594f2e2d59/html5/thumbnails/4.jpg)
• Meropenem 1.5g load then 1g tdsvs 500mg load then 3g/24hr CIV (3 x 8h infusions)
• Higher plasma and subcut. levels (black) with CIV.
Roberts et al JAC 2009
![Page 5: The impact of 24hr infusions on clinical practice](https://reader033.fdocuments.us/reader033/viewer/2022060918/629939fb178ce1594f2e2d59/html5/thumbnails/5.jpg)
(Doses expressed as piperacillin content) Roberts et al critical care med 2009
• Piperacillin bolus 4g 6hrly vs 12-16g/24hr CIV
• Higher likelihood of PK/PD target attainment with CIV dosing in critically ill with normal renal function. (bolus target =60% T>MIC, CIV = 100% T>MIC)
![Page 6: The impact of 24hr infusions on clinical practice](https://reader033.fdocuments.us/reader033/viewer/2022060918/629939fb178ce1594f2e2d59/html5/thumbnails/6.jpg)
þFlucloxacillinýMeropenem
![Page 7: The impact of 24hr infusions on clinical practice](https://reader033.fdocuments.us/reader033/viewer/2022060918/629939fb178ce1594f2e2d59/html5/thumbnails/7.jpg)
National Advice• Advice for clinicians, pharmacy and
nursing staff on considerations for OPAT services– Drug stability, including design of studies– Use of buffers– Compounding– Procurement– Storage– Administration
Mark Santillo, Abi Jenkins and Conor Jamiesonhttps://www.sps.nhs.uk/wp-content/uploads/2018/07/OPAT-v1-April-18.pdf
![Page 8: The impact of 24hr infusions on clinical practice](https://reader033.fdocuments.us/reader033/viewer/2022060918/629939fb178ce1594f2e2d59/html5/thumbnails/8.jpg)
Citrate Buffer
3Ca2+
Ca2+- O-
O-
O-Ca2+
Ca2+
6Na+
![Page 9: The impact of 24hr infusions on clinical practice](https://reader033.fdocuments.us/reader033/viewer/2022060918/629939fb178ce1594f2e2d59/html5/thumbnails/9.jpg)
Citrate Buffer – potential issues
![Page 10: The impact of 24hr infusions on clinical practice](https://reader033.fdocuments.us/reader033/viewer/2022060918/629939fb178ce1594f2e2d59/html5/thumbnails/10.jpg)
Monitored blood results
• N = 11• No patient required CIV interruption
• Low Ca2+: 1 x deranged LFTs, 1 x Low Vitamin D
![Page 11: The impact of 24hr infusions on clinical practice](https://reader033.fdocuments.us/reader033/viewer/2022060918/629939fb178ce1594f2e2d59/html5/thumbnails/11.jpg)
Study 2:Clinical Outcomes• Design: Retrospective obervational study• Inclusion: Patient episodes treated with buffered CIV beta-lactams
on OPAT from July 2017-October 2018.• Outcomes: based on BSAC NORS Infection Outcomes
– Cured: Completed OPAT duration with resolution of infection and no long-term antibiotics
– Improved: Completed OPAT with partial resolution of infection but need for further follow-up OR required escalation of antimicrobial therapy.
– Failure: Progression or non-response of infection despite OPAT, required admissions, surgical intervention or died for any reason.
![Page 12: The impact of 24hr infusions on clinical practice](https://reader033.fdocuments.us/reader033/viewer/2022060918/629939fb178ce1594f2e2d59/html5/thumbnails/12.jpg)
CIV Flucloxacillin (8g or 12g/24hours) Primary Infective Diagnosis
Discitis without metalwork (MW)
Discitis with MW
Epidural abscess
Infected total knee replacement
Infective Endocarditis
Malignant otitis externa
Post op wound infection
Psoas abscess
Septicaemia
Spinal infection assoc with MW
Wound infection post op
Osteomyelitis surgically related
N= 18
![Page 13: The impact of 24hr infusions on clinical practice](https://reader033.fdocuments.us/reader033/viewer/2022060918/629939fb178ce1594f2e2d59/html5/thumbnails/13.jpg)
Benzylpenicillin• Single patient-episode of vascular surgery infection
treated with benzylpenicillin 9.6g/24hr (2 x 4.8g concurrent via a dual lumen PICC).
![Page 14: The impact of 24hr infusions on clinical practice](https://reader033.fdocuments.us/reader033/viewer/2022060918/629939fb178ce1594f2e2d59/html5/thumbnails/14.jpg)
Pip/taz 13.5g/24 hour CIV Primary Infective Diagnosis
0
2
4
6
8
10
12
14
16
Bronchiectasis DF NO OM DFOM Empyema Lung abscess Vascular graftinfection
![Page 15: The impact of 24hr infusions on clinical practice](https://reader033.fdocuments.us/reader033/viewer/2022060918/629939fb178ce1594f2e2d59/html5/thumbnails/15.jpg)
Outcomes
0
2
4
6
8
10
12
14
16
18
BenPen 4.8g/24h Fluclox 12g/24h Fluclox 8g/24h PipTaz 13.5g/24h
Cured
Fail
Improved
Hills and Snape Poster #2141
![Page 16: The impact of 24hr infusions on clinical practice](https://reader033.fdocuments.us/reader033/viewer/2022060918/629939fb178ce1594f2e2d59/html5/thumbnails/16.jpg)
Comparison with Historic CohortPiperacillin/tazobactamdose and indication Number Male % Mean age
Proportion “improved” or
“cured”13.5g/24 hours CIV Bronchiectasis 15 53.3% 74.2 years 86.7%*
4.5g three times a day Bronchiectasis 53 41.5% 69.5 years 83.3%*
13.5g/24 hours CIV Diabetic foot osteomyelitis
11 63.6% 62.9 years 81.8%**
4.5g three times a day Diabetic foot osteomyelitis
28 63.0% 61.0 years 60%**
*p=0.73 **p=0.21(Chi squared test) .
![Page 17: The impact of 24hr infusions on clinical practice](https://reader033.fdocuments.us/reader033/viewer/2022060918/629939fb178ce1594f2e2d59/html5/thumbnails/17.jpg)
Clinical outcomes: Study 3• 35 Patient episodes piperacillin/tazobactam
elastomeric CIV treating PsA infections Jan 2015-Dec 2017 on OPAT.
• Resp 42.9%, SSTI 34.6%, Urinary 25.7%, OA 2.9%
J Ferreiro et al Poster #2140
![Page 18: The impact of 24hr infusions on clinical practice](https://reader033.fdocuments.us/reader033/viewer/2022060918/629939fb178ce1594f2e2d59/html5/thumbnails/18.jpg)
J Ferreiro et al Poster #2140
![Page 19: The impact of 24hr infusions on clinical practice](https://reader033.fdocuments.us/reader033/viewer/2022060918/629939fb178ce1594f2e2d59/html5/thumbnails/19.jpg)
Where are we now and for the future?
• Bringing aseptic dispensing of CIVs in-house.– Pilot 7 week study annualised saved us 170 bed days, £5k
• Review of need for additional bloods as limited effects seen (with current citrate loads).– ?Focus on higher risk patient– ?Continue with adjusted calcium monitoring?
• Drug stability work on Piperacillin/Tazobactam and Ceftazidime
![Page 20: The impact of 24hr infusions on clinical practice](https://reader033.fdocuments.us/reader033/viewer/2022060918/629939fb178ce1594f2e2d59/html5/thumbnails/20.jpg)
Summary• CIV beta lactams are a rational, efficacious option
which support OPAT patient care and service delivery.• Stability data is required to support their use
particularly in body-worn devices
![Page 21: The impact of 24hr infusions on clinical practice](https://reader033.fdocuments.us/reader033/viewer/2022060918/629939fb178ce1594f2e2d59/html5/thumbnails/21.jpg)
• Any Questions?